title: Clinical and laboratory examinations in the subgroups of chronic urticaria.
abstract: BACKGROUND
  The aetiology of chronic urticaria is heterogeneous. Physical urticaria (PU) is estimated at around 35%, autoimmune urticaria (AIU) at 25% and chronic idiopathic urticaria (CIU) at 35% of all chronic urticaria cases.
  
  
  METHODS
  Differences in clinical and laboratory parameters among AIU, PU and CIU groups were examined. AIU was diagnosed if the basophil CD63 assay was positive. Demographic data, severity of symptoms and association with allergic and autoimmune diseases were analysed by the aid of a questionnaire. Immunoassays were carried out and the effectiveness of therapy was also investigated.
  
  
  RESULTS
  Concerning the urticaria score, AIU patients had significantly higher total urticaria scores than patients with CIU (p = 0.013), dermatographic urticaria (p = 0.05) or cholinergic urticaria (p = 0.038). Between CIU and dermatographic urticaria and between CIU and cholinergic urticaria patients, we found insignificant differences in the urticaria score (p = 0.707 and p = 0.336, respectively). AIU was more frequently associated with autoimmune diseases in the personal history (p < 0.001) and with other types of urticaria in the family history (p < 0.001). Also, anti-thyroid antibodies were more frequently detected in the AIU group. Antihistamine therapy was less effective in the AIU group (12.8%) than in the PU (70.3%) and CIU groups (68.6%), but there were no significant differences between the CIU and PU groups regarding the effectiveness of antihistamine therapy.
  
  
  CONCLUSIONS
  The autoimmune subgroup represents the most severe form of chronic urticaria. On the other hand, there were no significant differences between the CIU and PU groups neither in urticaria scores nor in response to antihistamine therapy.
authors.affiliation: Department of Dermatology, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary.
authors.forename: Beatrix
authors.initials: B
authors.lastname: Irinyi
authors.forename: György
authors.initials: G
authors.lastname: Széles
authors.forename: Edit
authors.initials: E
authors.lastname: Gyimesi
authors.forename: Judit
authors.initials: J
authors.lastname: Tumpek
authors.forename: Emese
authors.initials: E
authors.lastname: Herédi
authors.forename: Georgitsis
authors.initials: G
authors.lastname: Dimitrios
authors.forename: Róza
authors.initials: R
authors.lastname: Adány
authors.forename: János
authors.initials: J
authors.lastname: Hunyadi
authors.forename: Andrea
authors.initials: A
authors.lastname: Szegedi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis / Q000096:biosynthesis; D001327:Autoimmune Diseases / Q000145:classification* / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D002908:Chronic Disease; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010980:Platelet Membrane Glycoproteins / Q000032:analysis / Q000096:biosynthesis; D060149:Tetraspanin 30; D014581:Urticaria / Q000145:classification* / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy
chemical_list: D015703:Antigens, CD; C554586:CD63 protein, human; D010980:Platelet Membrane Glycoproteins; D060149:Tetraspanin 30